Tuesday, 05 July 2016 06:31

Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?

By  Hofstra and Wetzels
Rate this item
(2 votes)

Patients with nephrotic syndrome are at increased risk of thrombosis. The risk of venous thrombosis is particularly high in patients with nephrotic syndrome due to primary membranous nephropathy. Recent data provide evidence that these patients also have a high absolute risk of arterial thrombotic events, which is associated with the degree of hypoalbuminemia. In this commentary we discuss whether prophylactic aspirin therapy might be indicated in this patient population.

 

Authors: Julia M. Hofstra and Jack F.M. Wetzels

Reference: Kidney International (2016) 89, 981–983; doi: 10.1016/j.kint.2016.01.019

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Source: KI
  • Year: 2016
  • Members Only: No
Read 3329 times

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact